Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Post-operative Haloperidol Versus Placebo for Prevention of Post-operative Delirium After Acute Hip Surgery

This study has been completed.
Information provided by:
Bronovo Hospital Identifier:
First received: November 7, 2005
Last updated: August 6, 2009
Last verified: August 2009
In this study the investigators want to determine if treatment with haloperidol direct post-operatively after acute hip surgery in high risk patients protects against developing a post-operative delirium.

Condition Intervention Phase
Post-Operative Delirium
Hip Fracture
Drug: Haloperidol
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: Randomised Double-blind Placebo-controlled Study of Post-operative Haloperidol Versus Placebo for Prevention of Post-operative Delirium After Acute Hip Surgery

Resource links provided by NLM:

Further study details as provided by Bronovo Hospital:

Primary Outcome Measures:
  • Incidence of post-operative delirium [ Time Frame: 72 hours post surgery ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Length of stay [ Time Frame: days ] [ Designated as safety issue: No ]
  • Complications [ Time Frame: during hospitalization ] [ Designated as safety issue: Yes ]

Enrollment: 220
Study Start Date: November 2005
Study Completion Date: February 2009
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A
Patients receiving blinded medication (Haloperidol or Placebo)
Drug: Haloperidol
Haloperidol 1mg twice daily during 72hours
Placebo Comparator: B
Patients receiving blinded medication (Haloperidol or Placebo)
Drug: placebo
Placebo 1mg twice daily during 72hours

Detailed Description:
A post-operative delirium is a serious and frequent (35-65%) complication with high morbidity and mortality in high risk patients. In this study we investigate whether we can prevent a delirium from occuring after surgery in patients with a hip fracture of 75 years of age and older. It's a randomised double-blind single centre placebo-controlled study of haloperidol versus placebo.

Ages Eligible for Study:   75 Years and older   (Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Hip fracture
  • 75 years and older

Exclusion Criteria:

  • Contra-indications for the use of haloperidol
  • Pre-operative delirium
  • Pre-operative use of haloperidol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00250237

Bronovo Hospital
The Hague, Zuid Holland, Netherlands, 2597 AX
Sponsors and Collaborators
Bronovo Hospital
Principal Investigator: Boke Linso Sjirk Borger van der Burg, MD Bronovo Hospital
  More Information

Responsible Party: Department of Surgery, Bronovo Hospital Identifier: NCT00250237     History of Changes
Other Study ID Numbers: 05-56 
Study First Received: November 7, 2005
Last Updated: August 6, 2009
Health Authority: Netherlands: Medical Ethics Review Committee (METC)

Keywords provided by Bronovo Hospital:
Post-operative delirium
hip fracture

Additional relevant MeSH terms:
Hip Fractures
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Neurocognitive Disorders
Mental Disorders
Femoral Fractures
Fractures, Bone
Wounds and Injuries
Hip Injuries
Leg Injuries
Haloperidol decanoate
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents processed this record on October 28, 2016